Biomeme
Biomeme is a Philadelphia-based molecular diagnostics company founded in 2012 that builds portable PCR and isothermal platforms for CBRN biodefense, clinical diagnostics, pharma, conservation research, and consumer wellness, monetizing hardware, consumables, licensing, and CLIA lab services.
- Company typePrivate
- Founded2012
- HeadquartersPhiladelphia, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Biomeme does
Biomeme is a Philadelphia-based molecular diagnostics company founded in 2012 that designs and manufactures portable real-time PCR thermocyclers and isothermal amplification platforms for field-deployable DNA/RNA detection. Its core hardware includes the Franklin ISP (MIL-STD-810G ruggedized, battery-operated, ~1.9–3 lbs) and the next-generation Biomeme/5 isothermal platform, paired with proprietary M1 Sample Prep cartridges that extract purified nucleic acids in 1–2 minutes without lab equipment or cold chain, DTECT isothermal amplification chemistry, and shelf-stable lyophilized reagents stable for up to 3 years at 30°C. An open-architecture Go-Strips assay system allows researchers and partners to run custom primers, and a cloud portal aggregates results from hundreds of distributed test sites in real time. The company holds 8+ US patents covering sample prep, analytic devices, and cartridges.
The company sells hardware and consumables (e.g., M1 Cartridge Kit at $450 per 30 samples) directly via shop.biomeme.com and through enterprise sales to government defense and CBRN biodefense customers (SOCOM, Department of War, National Guard, DARPA, DTRA, DHS), healthcare and clinical diagnostic providers (via One Health Labs CLIA-certified services), pharmaceutical and biotech firms (companion diagnostics, clinical trials support, RADICAL 510k study with ARLG/DCRI), research and conservation organizations (Wildlife Conservation Society, Cornell, Monash, Bigelow Laboratory), and consumer wellness users (GLP-1 response, longevity, athletic performance on Biomeme/5). Revenue streams include hardware sales, recurring consumables (Go-Strips, M1 cartridges, lyophilized master mixes), licensing and royalties (exclusive global INDICAL Bioscience agreement for animal health, Smith-Root integration for fisheries eDNA), pharma partnership and companion diagnostic co-development, and managed CLIA lab services. The company has wholly owned subsidiaries One Health Labs (CLIA-certified lab) and Predigen (host response diagnostics, acquired 2021 from Duke University), and has received a $3M Pennsylvania RACP grant and a portion of FIND's $21M LMIC diagnostics investment.
Biomeme firmographics
Firmographics- Name
- Biomeme
- Legal name
- Biomeme, Inc.
- Website
- https://biomeme.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Biomeme is a Philadelphia-based molecular diagnostics company founded in 2012 that builds portable PCR and isothermal platforms for CBRN biodefense, clinical diagnostics, pharma, conservation research, and consumer wellness, monetizing hardware, consumables, licensing, and CLIA lab services.
- Ownership category
- akta.pro rank
Biomeme industry classification
Industry- Product category
- Portable Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
Keywords
Where Biomeme is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Biomeme business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Molecular Testing Hardware Sales: Sale of portable PCR and isothermal amplification devices (Franklin ISP, Biomeme/5) and accessories directly to customers via e-commerce and sales team. One-time hardware purchase with optional upgrade paths.
- Consumables & Reagents: Recurring revenue from consumable assay kits (Go-Strips, M1 Sample Prep Cartridge Kits), lyophilized master mixes, and buffer reagents. Consumables are sold in kits (e.g., 30-sample M1 cartridge kit at $450) and drive recurring purchasing patterns.
- Pharma Partnership & Companion Diagnostics: Co-development partnerships with pharmaceutical companies for host response diagnostics, transcriptomic biomarker discovery, and companion diagnostics. Includes regulatory strategy support and transition from research-use-only to clinical-grade companion diagnostics.
- CLIA-Certified Lab Services via One Health Labs: CLIA-certified laboratory processing of samples using Biomeme technology, enabling clinics and healthcare providers to offer molecular diagnostics at point-of-care without operating their own lab.
- Technology Licensing (Open Platform): Open platform licensing model allowing third parties (researchers, assay developers) to use Biomeme's hardware and chemistry with their own primers and assays, generating licensing and reagent revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | M1 Sample Prep Cartridge Kit — $450 for 30 samples |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels10 records
Biomeme product offering
Product offeringCore offering
Biomeme designs, manufactures, and sells portable molecular diagnostics hardware (Franklin ISP real-time PCR thermocycler, Franklin handheld thermocycler, Biomeme/5 isothermal amplification platform) along with proprietary sample preparation cartridges (M1), lyophilized reagents (DTECT chemistry, LyoDNA/LyoRNA), and assay kits (Go-Strips, SARS-CoV-2 RT-PCR test, HR-B/V host response test). The platform is built for field-deployed, lab-grade molecular testing in biodefense, clinical, research, and consumer wellness applications, supported by cloud-connected data management software and CLIA-certified lab services through its One Health Labs subsidiary.
Product overview
Biomeme offers a molecular diagnostics platform comprising portable real-time PCR and isothermal amplification instruments (Franklin ISP, Franklin, and Biomeme/5), proprietary DTECT chemistry for shelf-stable reagents, and配套 sample preparation solutions (M1 Sample Prep Cartridge Kits, Go-Kits). The platform supports multiplexed molecular testing with up to 60 targets and delivers results in under 15 minutes to under an hour depending on the system. Assay offerings include FDA-authorized SARS-CoV-2 tests, host response diagnostics (HR-B/V), and vector/pathogen panels. Cloud-connected software enables remote monitoring and data management across distributed testing sites.
Differentiator
Problem solved
Functional benefit
Brands
- DTECT: Isothermal amplification chemistry technology for molecular testing
- One Health Labs
- Franklin
- Biomeme/5
- M1 Sample Prep
- Go-Strips
Quantifiable outcome
- 60-target multiplexed gene expression panels per sample with results in under 15 minutes
- +5 more outcomes
Companies that use Biomeme
Customer profileNamed customers34 records
Segments6 records
Ideal customer profiles5 records
Biomeme technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Biomeme partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and minor.
- Cornell UniversitycoreLong-standing academic research partnership with Cornell University, including water quality monitoring research with Dr. Ruth Richardson's lab developing new water monitoring technology for recreational water safety. Also involved in environmental DNA (eDNA) applications for beach safety.
- Monash UniversitycoreAcademic research partnership with Monash University for molecular testing platform development and field research applications.
- DARPAcoreDARPA is backing Biomeme's molecular testing platform development, reflecting confidence in the technology for defense and biodefense applications.
- Defense Threat Reduction Agency (DTRA)coreDTRA partnership supports Biomeme's development of molecular diagnostics for defense threat reduction applications.
- Department of Homeland SecuritycorePartnership with DHS through the Cross-Border Threat Screening and Supply Chain Defense Center of Excellence for biosurveillance and threat screening.
- CDMRP (Congressionally Directed Medical Research Programs)minorCDMRP partnership supporting medical research applications of Biomeme's molecular testing technology.
- FINDDxcoreFIND (global alliance for diagnostics) partnered with Biomeme as part of a $21 million investment to accelerate affordable, multi-pathogen, molecular diagnostic testing in low- and middle-income countries (LMICs). Biomeme is a key technology partner in this initiative.
- INDICAL BiosciencecoreExclusive global licensing and research agreement. INDICAL (formerly QIAGEN's veterinary diagnostic business) immediately adapts Biomeme's molecular point-of-need testing technology for its veterinary and animal protein production customers. This is an exclusive global arrangement covering animal health and food production.
- Smith-RootcoreSmith-Root, the leading organization in fishery conservation technology, integrates Biomeme's device and data management systems into the ANDe system for eDNA capture and species detection of endangered turtles and aquatic organisms. Partnership featured in Methods.blog (Methods in Ecology and Evolution journal).
- Wildlife Conservation SocietycoreWCS uses Biomeme for environmental DNA testing, wildlife conservation monitoring, species barcoding for illegal trade prevention, and canine distemper virus validation on the Biomeme platform. Dr. Tracie Seimon's team has developed multiple Biomeme test kits for conservation applications.
- BiovacminorBiovac partnership for vaccine and immunobiology research applications of molecular diagnostics technology.
- InnovaPrepminorInnovaPrep partnered with Biomeme to pair their expertise in liquid concentration for beverage quality control with Biomeme's portable real-time PCR platform, providing integrated solutions for food and beverage quality testing.
- Predigen (Duke University Spinout)coreBiomeme signed a definitive agreement to acquire Predigen, a Duke University global leader in host gene expression signatures. The merger enables point-of-care delivery of host response tests that address critical unmet needs in healthcare, particularly for differentiating bacterial vs. viral infections.
- One Health LabscoreOne Health Labs provides CLIA-certified lab processing, enabling clinics and healthcare providers to offer transcriptomic insights and molecular diagnostics at point-of-care without shipping samples to a central lab. Biomeme and One Health Labs are closely integrated subsidiaries.
- MRIGlobalcoreMRIGlobal collaborated with Biomeme to develop the 'Mercury Lab' — a backpack-enabled molecular biosurveillance system. Biomeme's two3 mobile thermocycler and M1 sample prep were integrated for field arbovirus surveillance in Everglades National Park, including detection of VEE virus and Everglades Virus.
- Ginkgo BioworksminorPartnership with Ginkgo Bioworks for K-12 school reopening using Biomeme's SARS-CoV-2 testing technology during the COVID-19 pandemic.
- Antibacterial Resistance Leadership Group (ARLG)coreARLG (a clinical research network supported by NIAID) partnered with Biomeme for the RADICAL 510k clinical study alongside Duke Clinical Research Institute to assess Biomeme's Host Response test for differentiating bacterial vs. viral infections.
- Duke Clinical Research Institute (DCRI)coreDCRI partnered with Biomeme and ARLG for the RADICAL 510k clinical study, providing clinical research expertise and oversight for Biomeme's Host Response diagnostic platform validation.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
Biomeme competitors and assessment
Company assessmentBroad incumbents
- Abbott (ID NOW, m-PIMA): Abbott's ID NOW isothermal platform and m-PIMA are widely deployed POC molecular systems. Abbott operates across the broader diagnostics portfolio, including core lab and rapid tests where Biomeme does not compete.
- Hologic (Panther Fusion): Hologic's Panther Fusion system provides high-throughput molecular diagnostics for clinical labs and women's health. A broader incumbent whose centralized lab footprint contrasts with Biomeme's portable positioning.
- Qiagen: Qiagen is the global leader in sample-prep and PCR reagents and previously owned the INDICAL veterinary business now licensing Biomeme's platform. Overlapping in consumables chemistry, instrumentation, and molecular workflow tools.
Direct peers
- bioMérieux BioFire: BioFire's FilmArray panels dominate syndromic molecular diagnostics in hospitals. Biomeme targets overlapping pathogen-detection use cases with a portable platform optimized for field and resource-limited settings where FilmArray is impractical.
- Cepheid (Danaher): Cepheid's GeneXpert system is the established gold-standard for PCR-based molecular diagnostics across clinical and biodefense settings. Biomeme competes for the same end-user workflows with a portable, field-ruggedized form factor that GeneXpert cannot match.
- Roche (cobas Liat): Roche's cobas Liat is the most direct point-of-care PCR competitor — a compact, rapid molecular system used in urgent care and pharmacy settings. Comparable in form factor and workflow to Biomeme's Franklin platform.
- Cue Health: Cue Health built a connected, cartridge-based molecular POC platform during COVID-19 with FDA EUA for home and professional use. Direct competitor in the portable, cloud-connected PCR category where Biomeme also operates.
Emerging players
- T2 Biosystems: T2 Biosystems provides rapid molecular diagnostics for sepsis and other bloodstream infections directly from whole blood. Comparable in rapid-molecular differentiation and clinical decision-support, though focused on centralized hospital use rather than field deployment.
- Sherlock Biosciences: Sherlock is developing CRISPR-based molecular diagnostics for point-of-care and at-home use. Emerging player with overlapping molecular POC ambitions but differentiated by CRISPR SHERLOCK/DETECTR chemistry rather than PCR.
- Mesa Labs: Mesa Labs' Accelerate Diagnostics portfolio targets rapid identification of bloodstream and antibiotic-resistance pathogens. Adjacent in rapid clinical molecular diagnostics though primarily centralized lab rather than portable.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biomeme social profiles
Digital presenceBiomeme compliance and trust
Trust signalCompliance4 records
Biomeme financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomeme leadership team
Management profileNumber of profiles
Profiles8 records
Biomeme subsidiaries and ownership
Company hierarchySubsidiaries2 records
Biomeme funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomeme M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomeme
What does Biomeme do?
Biomeme designs, manufactures, and sells portable molecular diagnostics hardware (Franklin ISP real-time PCR thermocycler, Franklin handheld thermocycler, Biomeme/5 isothermal amplification platform) along with proprietary sample preparation cartridges (M1), lyophilized reagents (DTECT chemistry, LyoDNA/LyoRNA), and assay kits (Go-Strips, SARS-CoV-2 RT-PCR test, HR-B/V host response test). The platform is built for field-deployed, lab-grade molecular testing in biodefense, clinical, research, and consumer wellness applications, supported by cloud-connected data management software and CLIA-certified lab services through its One Health Labs subsidiary.
Is Biomeme a public or private company?
Biomeme is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biomeme founded?
Biomeme was founded in 2012. It employs 51 to 100 people.
Where is Biomeme based?
Biomeme is headquartered in Philadelphia, United States, in the North America region.
How does Biomeme make money?
Five revenue lines are on record. Molecular Testing Hardware Sales are the primary driver. The others are consumables & Reagents, pharma Partnership & Companion Diagnostics, CLIA-Certified Lab Services via One Health Labs and technology Licensing (Open Platform).
Who are Biomeme's main competitors?
Broad incumbents on record are Abbott (ID NOW, m-PIMA), Hologic (Panther Fusion) and Qiagen. Direct peers are bioMérieux BioFire, Cepheid (Danaher), Roche (cobas Liat) and Cue Health. Emerging players are T2 Biosystems, Sherlock Biosciences and Mesa Labs.
Does Biomeme have an API?
No public API is recorded for Biomeme.
What industry is Biomeme in?
Biomeme's product category is Portable Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.